STANFORD’S REVIEW OF THE 61ST ANNUAL
AMERICAN SOCIETY OF HEMATOLOGY MEETING
Saturday, February 15, 2020 • 7:30 am – 4:45 pm
The Ritz-Carlton, Half Moon Bay, CA

COURSE DIRECTORS
Jason Gotlib, MD, MS
Professor of Medicine, Hematology
Michaela Liedtke, MD
Associate Professor of Medicine, Hematology

STANFORD FACULTY
Ranjana Advani, MD
Saul A. Rosenberg Professor of Lymphoma, Stanford Cancer Institute
Caroline Berube, MD
Clinical Associate Professor of Medicine, Hematology
Medical Director, Oral Anticoagulation Clinic
May Chien, MD
Instructor, Pediatrics - Hematology & Oncology
Steven Coutre, MD
Professor of Medicine, Hematology
Director of Hematology Clinic

FACULTY
All faculty members are from Stanford University School of Medicine unless otherwise noted.

Stefan Schrier Memorial \nJason Gotlib, MD, MS

Keynote Lecture: Stem Cells in Human AML \nRavi Majeti, MD, PhD

Non-Malignant Hematology Case-Based Panel Discussion With Q&A \nMarie Hollenhorst, MD, PhD and May Chien, MD (Moderators), Caroline Berube, MD, and Lawrence Leung, MD

Focus on New Drug Approvals \nTBD

Molecular Hematopathology Tumor Board \nWilliam Shomali, MD (Moderator), Gerlinde Wernig, MD, PhD and May Chien, MD (Moderators), Caroline Berube, MD, and Lawrence Leung, MD

Register today! stanford.cloud-cme.com/hematology2020
**LEARNING OBJECTIVES**

- Evaluate the use of new chemotherapeutics and biologic regimens in sub-populations of acute myeloid leukemia patients based on patient clinical and genetic profiles and treatment goals
- Apply treatment strategies that optimally utilize JAK inhibitors and other novel agents in patients with myeloproliferative neoplasms (MPN) and systemic mastocytosis
- Evaluate optimal sequencing and combinations of novel biologics for chronic lymphocytic leukemia
- Update the application and interpretation of minimal residual disease (MRD) testing in hematologic malignancies, including AML, myeloma, and CLL
- Incorporate available therapeutic options for patients with low- or high-risk myelodysplastic syndromes and utilize the revised international prognostic scoring system (IPSS-R) with new mutation data to classify patients for treatment
- Determine the best combination regimens, novel agents, and new antibody therapies for different populations of newly diagnosed and relapsed/refractory myeloma patients, including patients who are transplant eligible and transplant ineligible
- Evaluate the results of phase I/II trials in Hodgkin and non-Hodgkin lymphomas
- Evaluate the latest efficacy and safety data for use of direct oral anticoagulants for patients with non-malignant hematologic indications as well as cancer patients with thrombosis
- Use a case-based tumor-board approach to illustrate how clinical presentation, histopathology, and molecular diagnostics can be used to inform diagnosis, prognosis, and treatment of patients with blood disorders
- Review new drug approvals for patients with non-malignant and malignant hematologic indications, highlighting approved indications, key efficacy endpoints, and safety profile

---

**ATTENDEE TYPE**

<table>
<thead>
<tr>
<th>ATTENDEE TYPE</th>
<th>FEE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians, Nurses &amp; Allied Health Professionals</td>
<td>$195</td>
</tr>
</tbody>
</table>

**CANCELLATION POLICY**

Cancellations received in writing no less than 20 days before the course will be refunded, less a 20% administrative fee. No refunds will be made on cancellations received after that date. Please send cancellation requests to stanfordcme@stanford.edu.

Stanford University School of Medicine reserves the right to cancel or postpone this program if necessary; in the event of cancellation, course fees will be fully refunded. We are not responsible for other costs incurred such as non-refundable airline tickets or hotel penalties.

**CONTACT INFORMATION**

For questions about the symposium, please contact Melissa Schwartz, Compliance and Meeting Planning Specialist at (650) 724-2288 or melissa.schwartz@stanford.edu

Stanford Center for Continuing Medical Education
1520 Page Mill Road, Palo Alto, CA 94304
Phone: (650) 497-8554 • Fax: (650) 497-8585
Email: stanfordcme@stanford.edu • Web: cme.stanford.edu

**ACCESSIBILITY STATEMENT**

Stanford University School of Medicine is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008. If you have needs that require special accommodations, including dietary concerns, please contact the CME Conference Coordinator.